A New Hope in Immunotherapy for Malignant Gliomas: Adoptive T Cell Transfer Therapy
Immunotherapy emerged as a promising therapeutic approach to highly incurable malignant gliomas due to tumor-specific cytotoxicity, minimal side effect, and a durable antitumor effect by memory T cells. But, antitumor activities of endogenously activated T cells induced by immunotherapy such as vacc...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2014/326545 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562950593839104 |
|---|---|
| author | Dong-Sup Chung Hye-Jin Shin Yong-Kil Hong |
| author_facet | Dong-Sup Chung Hye-Jin Shin Yong-Kil Hong |
| author_sort | Dong-Sup Chung |
| collection | DOAJ |
| description | Immunotherapy emerged as a promising therapeutic approach to highly incurable malignant gliomas due to tumor-specific cytotoxicity, minimal side effect, and a durable antitumor effect by memory T cells. But, antitumor activities of endogenously activated T cells induced by immunotherapy such as vaccination are not sufficient to control tumors because tumor-specific antigens may be self-antigens and tumors have immune evasion mechanisms to avoid immune surveillance system of host. Although recent clinical results from vaccine strategy for malignant gliomas are encouraging, these trials have some limitations, particularly their failure to expand tumor antigen-specific T cells reproducibly and effectively. An alternative strategy to overcome these limitations is adoptive T cell transfer therapy, in which tumor-specific T cells are expanded ex vivo rapidly and then transferred to patients. Moreover, enhanced biologic functions of T cells generated by genetic engineering and modified immunosuppressive microenvironment of host by homeostatic T cell expansion and/or elimination of immunosuppressive cells and molecules can induce more potent antitumor T cell responses and make this strategy hold promise in promoting a patient response for malignant glioma treatment. Here we will review the past and current progresses and discuss a new hope in adoptive T cell therapy for malignant gliomas. |
| format | Article |
| id | doaj-art-69c29af3e89a400e9ef88bad22cf5b75 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-69c29af3e89a400e9ef88bad22cf5b752025-02-03T01:21:24ZengWileyJournal of Immunology Research2314-88612314-71562014-01-01201410.1155/2014/326545326545A New Hope in Immunotherapy for Malignant Gliomas: Adoptive T Cell Transfer TherapyDong-Sup Chung0Hye-Jin Shin1Yong-Kil Hong2Department of Neurosurgery, Incheon St. Mary’s Hospital, The Catholic University of Korea College of Medicine, Dongsuro 56, Bupyeong-gu, Incheon 403-720, Republic of KoreaDepartment of Neurosurgery, Seoul St. Mary’s Hospital, The Catholic University of Korea College of Medicine, Banpodaero 222, Seocho-gu, Seoul 137-701, Republic of KoreaDepartment of Neurosurgery, Seoul St. Mary’s Hospital, The Catholic University of Korea College of Medicine, Banpodaero 222, Seocho-gu, Seoul 137-701, Republic of KoreaImmunotherapy emerged as a promising therapeutic approach to highly incurable malignant gliomas due to tumor-specific cytotoxicity, minimal side effect, and a durable antitumor effect by memory T cells. But, antitumor activities of endogenously activated T cells induced by immunotherapy such as vaccination are not sufficient to control tumors because tumor-specific antigens may be self-antigens and tumors have immune evasion mechanisms to avoid immune surveillance system of host. Although recent clinical results from vaccine strategy for malignant gliomas are encouraging, these trials have some limitations, particularly their failure to expand tumor antigen-specific T cells reproducibly and effectively. An alternative strategy to overcome these limitations is adoptive T cell transfer therapy, in which tumor-specific T cells are expanded ex vivo rapidly and then transferred to patients. Moreover, enhanced biologic functions of T cells generated by genetic engineering and modified immunosuppressive microenvironment of host by homeostatic T cell expansion and/or elimination of immunosuppressive cells and molecules can induce more potent antitumor T cell responses and make this strategy hold promise in promoting a patient response for malignant glioma treatment. Here we will review the past and current progresses and discuss a new hope in adoptive T cell therapy for malignant gliomas.http://dx.doi.org/10.1155/2014/326545 |
| spellingShingle | Dong-Sup Chung Hye-Jin Shin Yong-Kil Hong A New Hope in Immunotherapy for Malignant Gliomas: Adoptive T Cell Transfer Therapy Journal of Immunology Research |
| title | A New Hope in Immunotherapy for Malignant Gliomas: Adoptive T Cell Transfer Therapy |
| title_full | A New Hope in Immunotherapy for Malignant Gliomas: Adoptive T Cell Transfer Therapy |
| title_fullStr | A New Hope in Immunotherapy for Malignant Gliomas: Adoptive T Cell Transfer Therapy |
| title_full_unstemmed | A New Hope in Immunotherapy for Malignant Gliomas: Adoptive T Cell Transfer Therapy |
| title_short | A New Hope in Immunotherapy for Malignant Gliomas: Adoptive T Cell Transfer Therapy |
| title_sort | new hope in immunotherapy for malignant gliomas adoptive t cell transfer therapy |
| url | http://dx.doi.org/10.1155/2014/326545 |
| work_keys_str_mv | AT dongsupchung anewhopeinimmunotherapyformalignantgliomasadoptivetcelltransfertherapy AT hyejinshin anewhopeinimmunotherapyformalignantgliomasadoptivetcelltransfertherapy AT yongkilhong anewhopeinimmunotherapyformalignantgliomasadoptivetcelltransfertherapy AT dongsupchung newhopeinimmunotherapyformalignantgliomasadoptivetcelltransfertherapy AT hyejinshin newhopeinimmunotherapyformalignantgliomasadoptivetcelltransfertherapy AT yongkilhong newhopeinimmunotherapyformalignantgliomasadoptivetcelltransfertherapy |